[go: up one dir, main page]

WO2001035979A3 - Combined pde3 and pde4 inhibitor therapy for the treatment of obesity - Google Patents

Combined pde3 and pde4 inhibitor therapy for the treatment of obesity Download PDF

Info

Publication number
WO2001035979A3
WO2001035979A3 PCT/US2000/042137 US0042137W WO0135979A3 WO 2001035979 A3 WO2001035979 A3 WO 2001035979A3 US 0042137 W US0042137 W US 0042137W WO 0135979 A3 WO0135979 A3 WO 0135979A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
treatment
pde4 inhibitor
inhibitor therapy
pde3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/042137
Other languages
French (fr)
Other versions
WO2001035979A2 (en
Inventor
Peter Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Priority to AU32703/01A priority Critical patent/AU3270301A/en
Publication of WO2001035979A2 publication Critical patent/WO2001035979A2/en
Publication of WO2001035979A3 publication Critical patent/WO2001035979A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides materials and methods for the treatment of obesity that involve a combination of a PDE3 and PDE4 inhibitor in synergistically effective amounts.
PCT/US2000/042137 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity Ceased WO2001035979A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU32703/01A AU3270301A (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16541899P 1999-11-13 1999-11-13
US60/165,418 1999-11-13

Publications (2)

Publication Number Publication Date
WO2001035979A2 WO2001035979A2 (en) 2001-05-25
WO2001035979A3 true WO2001035979A3 (en) 2002-01-03

Family

ID=22598815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042137 Ceased WO2001035979A2 (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU3270301A (en)
WO (1) WO2001035979A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
JP2004536614A (en) 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ PDE3 cyclic nucleotide phosphodiesterase isoform-selective inhibitors and activators
FR2849594B1 (en) * 2003-01-03 2006-10-27 Oreal USE OF ZARDAVERINE AS SLIMMING
MXPA06002521A (en) 2003-09-05 2006-06-20 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus.
WO2006063714A1 (en) * 2004-12-14 2006-06-22 Menarini Ricerche S.P.A. Pharmaceutical compositions for the treatment of cellulite
JP5091106B2 (en) 2005-03-08 2012-12-05 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Roflumilast for the treatment of diabetes mellitus
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
WO2009154230A1 (en) * 2008-06-17 2009-12-23 持田製薬株式会社 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US20130172356A1 (en) * 2010-06-23 2013-07-04 Kyushu University, National University Corporation Combination of egcg or methylated egcg and a pde inhibitor
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
IL263412B (en) * 2016-06-03 2022-08-01 Univ Columbia Treatment methods for Freder Willi syndrome
WO2020076752A1 (en) * 2018-10-08 2020-04-16 The Johns Hopkins University Use of pde9 inhibitors for treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOUSA M K ET AL: "Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection?.", CLINICAL NEPHROLOGY, (1997 MAR) 47 (3) 187-9., XP002168562 *
PAN X ET AL: "Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.", BIOCHEMICAL PHARMACOLOGY, (1994 AUG 17) 48 (4) 827-35., XP002168561 *
SCHMITZ-PEIFFER C ET AL: "Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells.", CELLULAR SIGNALLING, (1992 JAN) 4 (1) 37-49., XP002168563 *

Also Published As

Publication number Publication date
WO2001035979A2 (en) 2001-05-25
AU3270301A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
AU8870701A (en) Materials and methods for the treatment or prevention of obesity
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
AU6739001A (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
WO2002098416A3 (en) Antineoplastic combinations
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
PL375631A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
EE200300057A (en) Ingredients for the prevention and treatment of cancer
AU3735900A (en) Methods of treatment and prevention of restenosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase